褐藻糖胶通过抑制JNK和NF-κB活化减轻血管紧张素II诱导的腹主动脉瘤
该研究在血管紧张素II诱导的小鼠腹主动脉瘤模型中评估褐藻糖胶的治疗作用,发现其显著降低AAA发生率,使主动脉扩张从1.56±0.76 mm减小至1.09±0.30 mm,并抑制MMP-2/MMP-9活性及弹性蛋白降解。体外实验显示褐藻糖胶可减轻Ang II诱导的JNK和NF-κB p65磷酸化,减少MMP和活性氧产生。结论提示褐藻糖胶可能成为小AAA的潜在药物辅助治疗。
要点
- 褐藻糖胶显著降低Ang II诱导的小鼠AAA发生率。
- 褐藻糖胶使主动脉扩张从1.56±0.76 mm减小至1.09±0.30 mm。
- 褐藻糖胶抑制MMP-2/MMP-9活性并减轻弹性蛋白降解。
核心结论
- 褐藻糖胶通过减弱促炎性NF-κB和JNK活化抑制实验性AAA进展。
- 褐藻糖胶可能是小AAA的潜在药物辅助治疗。
研究设计与样本
- 采用血管紧张素II诱导的小鼠AAA模型评估褐藻糖胶的体内治疗效果。
- 使用人脐静脉内皮细胞进行体外通路研究。
- 通过Western blotting检测体内外相关信号通路。
主要发现
- 褐藻糖胶治疗显著降低AAA形成发生率。
- 褐藻糖胶使Ang II诱导的主动脉扩张从1.56±0.76 mm减小至1.09±0.30 mm。
- 褐藻糖胶显著抑制MMP-2和MMP-9活性并降低弹性蛋白降解等级。
- 体外实验中褐藻糖胶减轻Ang II诱导的JNK和NF-κB p65磷酸化,减少MMP和活性氧产生。
临床怎么用
- 为小AAA缺乏有效药物辅助治疗提供了潜在新选择。
- 提示靶向JNK和NF-κB通路的抗炎策略可能延缓AAA进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rupture of abdominal aortic aneurysm (AAA) is one of the leading causes of sudden death among the elderly. Most incidental AAAs are below the threshold for intervention at the time of detection; however, there is no evidence that commonly used cardiovascular drugs have clinical beneficial effects on AAA progression. Therefore, in addition to current cardiovascular risk-reducing treatments, an adjunctive medical therapy targeting the regulation of extracellular matrix metabolism is still required in the clinical setting. Fucoidan is an extract of brown seaweed and a sulfated polysaccharide. Emerging evidence suggests that fucoidan has potential cardiovascular applications. Numerous investigations of fucoidan in diseases of the cardiovascular system have mainly focused on its pleiotropic anti-inflammatory effects. Specifically, fucoidan has been shown to have matrix metalloproteinase (MMP)-reducing effects in several studies. We aimed to evaluate the beneficial effect of fucoidan on aneurysmal growth in a murine model of aortic aneurysm and further provide a rationale for using fucoidan as a medical adjunctive therapy. METHODS: A murine model of angiotensin II (Ang II)-induced AAA was used to assess the therapeutic effects of fucoidan on AAA growth in vivo. The characteristics and quantification of AAAs were determined in situ. Human umbilical vein endothelial cells were used for studying the involved pathways in vitro. Western blotting was used to detect the involved signaling pathways both in vivo and in vitro. RESULTS: Treatment with fucoidan significantly reduced the incidence of AAA formation. Administration of fucoidan significantly attenuated Ang II-induced aortic expansion from 1.56 ± 0.76 mm to 1.09 ± 0.30 mm. Administration of fucoidan significantly suppressed MMP-2 and MMP-9 activities and reduced the grade of elastin degradation in vivo. In vitro, we found that fucoidan could ameliorate the Ang II-induced phosphorylation of c-Jun N-terminal kinase and nuclear factor κB p65, and it further reduced MMP and reactive oxygen species production. CONCLUSIONS: Fucoidan inhibits the progression of experimental AAA growth through the attenuation of proinflammatory nuclear factor κB and c-Jun N-terminal kinase activation. Fucoidan could be a potential medical adjunctive therapy for small AAAs.
引用
- Tsai SH, Wang JC, Liao WI, et al. Fucoidan attenuates angiotensin II-induced abdominal aortic aneurysms through the inhibition of c-Jun N-terminal kinase and nuclear factor κB activation. J Vasc Surg. 2017. PMID: 29290496. doi:10.1016/j.jvs.2017.09.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。